検索結果

pan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed...

Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical

Communications with Customers and Provision of Information to Senju Pharmaceutical has a Customer Service Center for directly responding to inquiries from consumers and patients. The role of the Cente...

ry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designe...

pan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed...

Mytear PINT CARE EX Mild | OTC Products, etc. | Products | SENJU Pharmaceutical

and blurred vision CHARACTERISTICS Contains the maximum concentration* of neostigmine methylsulfate with a focus adjustment-improving effect. Effective for eyestrain and blurred vision (eye mucus) whi...